HealthQuiet 11d · day 11
Trump drug pricing policy could delay European medicine launches, study warns
US most-favored-nation pricing push may incentivize pharma companies to postpone rollouts in lower-price markets.
What to know
- A modelling study warns that Trump's most-favored-nation pricing policy could have unintended consequences for European access to new medicines.
- The policy aims to lower US drug prices by aligning them with lower prices in other developed countries, but may incentivize pharma companies to delay market launches in those lower-price regions.
- European patients could face longer waits for novel medicines as a result of the US pricing initiative.
“Last May, US President Donald Trump pushed to align drug pricing with the lowest levels among other developed nations — so-called most-favoured-nation (MFN) pricing. However, the pricing policy might have negative consequences.”
Euronews · Euronews ↗
Donald Trump US President
How it unfolded 1 development · click the chart to see its coverage articlesposts
Sep 15Sep 16Sep 17Sep 18Sep 19Sep 20Sep 21Sep 22Sep 23now · 8:49 AM ET
-
1
“European patients could face longer waits for some new medicines as US efforts to drive down drug prices risk encouraging pharmaceutical companies to delay launches in lower-price markets.”
— Euronews · source -
first by Euronews.com, 11d ago · also Euronews
-
-
background
Trump pushes most-favored-nation drug pricing policy — US President Donald Trump promoted alignment of drug pricing with the lowest levels among other developed nations through most-favored-nation (MFN) pricing.